In this manner, we performed subclass mapping of TCGA cohort and revealed that only the CS1 showed high transcriptome-level similarity to a group of patients with melanoma who responded to anti-CTLA4 or anti-PD1 blockades (P < 0.05, adjusted P ≤0.25; Figure 5C), which indicated that the current classification may be useful to identify ideal candidates of patients with colorectal cancer for immunotherapy. The gene discussed is CTLA4; the disease is colorectal cancer.